The United States FDA has granted approval for HeartMate 3 medical device (picture image on right side), made by Abbott Laboratories. The HeartMate 3 is the only approved device for VAD to support as "bridge to transplant" therapy. This device simulates the beating of heart (pulse) and helps patient's heart in pumping oxygen-rich blood to body organs including the heart and keeps the patient alive until the patient receives a heart transplant or a total artificial heart.
The functionality of this device is safer (with fewer complications) than traditional left ventricular assist device (LVAD) (or left-ventricular assist heart pumps). Clinical trial results of HeartMate 3 medical device were published in February 2017. The results show fewer device problems and strokes to the patient compared with other heart pump models of Abbott's.
Life expectancy of a heart failure patient without LVAD treatment will be 12 months or fewer. With LVAD, 80 to 85 percent of heart failure patients are alive even after 12 months and 70 to 75 percent of heart failure patients were survived even after 24 months. The longest survival period was observed with LVAD device was about 7 years.
Minnesota-run Medtronic also manufactures left-ventricular assist devices (LVADs) and is a competitor to Abbott's HeartMate 3 medical device. Cost of each LVAD is around $80,000 and hospitals are willing to pay.
LVAD : The left-ventricular assist device is an electromechanical device which helps heart failure patient in circulating oxygen-rich blood to body organs. Help to heart functionality can be partial or complete. They are different from artificial hearts. There are devices which can support right-ventricular of the heart called as right-ventricular assist device (RVAD). These devices are used as a bridge-to-transplantation and allow body systems and heart to rest, heal and improve its functionality.
Abbott Laboratories : Abbott Laboratories is an Illinois, the United States based multinational healthcare company. Founded in 1888 by Calvin Abbott and the company deals with diagnostics, branded generic pharmaceuticals, medical devices etc. Abbott Laboratories products are being used worldwide by doctors, hospitals, laboratories and blood banks to diagnose and monitor the health of an individual.
The human body uses sodium to perform multiple biological functions such as muscle flexing, nerves functionality and to maintain fluid balance. The human body requires little salt (as salt contains sodium). The human body receives some sodium from the food we eat. The World Health Organization (WHO) limits salt consumption to 5 grams per day. Too much of salt consumption is bad for the health of an individual. But the studies yet to find out the role of salt in increasing health risks.
A current study done by researchers shows a two-fold increased risk of heart failure with increased consumption of salt. The study also shows high amounts of salt consumption is associated with high blood pressure or hypertension and salt consumption is an independent risk factor for heart failure, stroke and coronary heart disease (CHD).
In the current study, researchers used "24-hour sodium excretion" method to judge salt consumption among 4,630 men and women individuals, aged between 25 to 64 from the Finish data available at the National FINRISK Study and the North Karelia Salt Study. At baseline, researchers collected participant's health habits, blood pressure (BP), height, body mass index (BMI), 24-hour urine samples, blood tests etc. They equated 1 gram sodium consumption to 17.1 millimoles (mmol) of excreted sodium from the collected 24 hour urine sample. Researchers followed their National Health Records for 12 years. They gathered new heart failure incidents and deaths related to heart failure from the Hospital Discharge Register, Causes-of-Death Register and the drug and treatment reimbursement records. They found 121 new heart failure incidents.
The study results show two times higher risk of heart failure among those individuals who consume more than 13.7 grams of salt compared to those individuals who consume less than 6.8 grams of salt. This heart failure risk with salt (or sodium) consumption is independent of other risks associated with blood pressure (BP) or hypertension. Researchers adjusted other risk factors in their results.
The first author of the study was Professor Pekka Jousilahti, MD, PhD, Department of Chronic Disease Prevention, the National Institute for Health and Welfare, Helsinki, Finland. The study findings were presented during August 2017, to the European Society of Cardiology (ESC) Congress in Barcelona, Spain. Title of the article was "High salt intake associated with doubled risk of heart failure."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.